RecruitingPhase 1NCT05433142
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Studying Clear cell papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xencor, Inc.
- Principal Investigator
- Chet Bohac, MDXencor, Inc.
- Intervention
- XmAb819(biological)
- Enrollment
- 307 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2028
Study locations (21)
- Xencor Investigative Site, Phoenix, Arizona, United States
- Xencor Investigative Site, Duarte, California, United States
- Xencor Investigative Site, Sacramento, California, United States
- Xencor Investigative Site, New Haven, Connecticut, United States
- Xencor Investigative Site, Jacksonville, Florida, United States
- Xencor Investigative Site, Atlanta, Georgia, United States
- Xencor Investigative Site, Chicago, Illinois, United States
- Xencor Investigative Site, Louisville, Kentucky, United States
- Xencor Investigative Site, Rochester, Minnesota, United States
- Xencor Investigative Site, New Brunswick, New Jersey, United States
- Xencor Investigative Site, New York, New York, United States
- Xencor Investigative Site, Charlotte, North Carolina, United States
- Xencor Investigative Site, Durham, North Carolina, United States
- Xencor Investigative Site, Cincinnati, Ohio, United States
- Xencor Investigative Site, Columbus, Ohio, United States
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05433142 on ClinicalTrials.govOther trials for Clear cell papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05665361Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)National Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05287945Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell CarcinomaOncorena AB
- ACTIVE NOT RECRUITINGPHASE1NCT05122546CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerCity of Hope Medical Center
See all trials for Clear cell papillary renal cell carcinoma →